Anavex Life Sciences Corp. (NASDAQ:$AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX2-73 with donepezil, ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, and ANAVEX 1519, and ANAVEX 1-66 being developed to treat Alzheimer’s disease and other central nervous system CNS diseases.
The company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis of a disease.
Anavex presently has a consensus price target of $15.00, while 24.5% of Anavex shares are owned by institutional investors, and 11.6% of Anavex shares are owned by insiders. Further, Anavex has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
A number of research firms have weighed in on AVXl as well. Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. Zacks Investment Research also lowered shares of Anavex, from a “buy” rating to a “hold” rating. ValuEngine lowered shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating.
Featured Image: twitter
